NeoImmuneTech네오이뮨텍
950220 · KOSDAQ · ₩950220 · 네오이뮨텍
₩1,632▼ ₩45 (2.68%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩66,673 | ₩124,917 | ₩0 | ₩0 | ₩0 |
| Cost of sales | ₩18M | ₩29M | ₩43M | ₩45M | −₩45M |
| Gross profit | −₩18M | −₩29M | −₩43M | −₩45M | −₩45M |
| Operating income | −₩18M | −₩29M | −₩43M | −₩45M | −₩45M |
| Net income | −₩22M | −₩30M | −₩41M | −₩47M | −₩46M |
| Net income to shareholders | −₩22M | −₩30M | −₩41M | −₩47M | −₩46M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩57M | ₩45M | ₩70M | ₩110M | ₩158M |
| Current assets | ₩44M | ₩27M | ₩56M | ₩93M | ₩141M |
| Cash and equivalents | ₩27M | ₩23M | ₩53M | ₩91M | ₩130M |
| Total liabilities | ₩16M | ₩16M | ₩12M | ₩16M | ₩21M |
| Current liabilities | ₩14M | ₩14M | ₩10M | ₩13M | ₩17M |
| Borrowings | ₩5.3M | ₩4.7M | ₩6M | ₩9.5M | ₩14M |
| Total equity | ₩41M | ₩28M | ₩58M | ₩94M | ₩137M |
| Shareholders' equity | ₩41M | ₩28M | ₩58M | ₩94M | ₩137M |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩18M | −₩29M | −₩39M | −₩33M | −₩29M |
| Capital spending | ₩56,000 | ₩1.1M | ₩613,764 | ₩2M | ₩2.3M |
| Free cash flow | −₩18M | −₩30M | −₩39M | −₩35M | −₩31M |
Consolidated where available. Amounts in won.
Also known as: NeoImmuneTech / 네오이뮨텍 / 950220 / KRX:950220
Source: KRX statistical information